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Summary. The development of inhibitors to the
infused factor in patients with haemophilia is a
serious clinical problem. Recent evidence suggests
that alongside the strong genetic contribution to
inhibitor formation, there are a number of non-
genetic factors – perceived by the immune system as
danger signals – which promote formation of inhib-
itors. This study provides a comprehensive review of
clinical studies relating to these factors and also
presents a survey of opinion concerning their impor-
tance and clinical influence, conducted among the
members of the European Haemophilia Treatment
Standardisation Board (EHTSB). Taken together,
this information highlights the lack of robust data
concerning the influence of several non-genetic risk
factors on inhibitor development, and an urgent need
for prospective, well-conducted studies that adhere
to recommendations made by the European Medi-
cines Agency (EMEA) for studying inhibitors. Based
on current literature, the EHTSB formulated consen-
sus recommendations. It is desirable to minimize
intensive treatment wherever possible, given the
clinical situation. Prophylaxis should be offered to
all children, although we still need to determine
optimal dosing with respect to inhibitor develop-
ment, and age for starting treatment. Vaccinations
should be given subcutaneously and concomitant
factor concentrate infusions avoided. According to
the board, there is no evidence in the literature
supporting suggestions that the type of concentrate
influences inhibitor risk; but all patients should be
monitored during their first exposures. Furthermore,
there is no evidence to support an association
between pregnancy-related issues, breast feeding
and treatment-related factors (e.g. route of adminis-
tration, or use of blood components) and inhibitor
development.
Keywords: EHTSB, haemophilia, inhibitors, non-
genetic, risk factors
Introduction
A major challenge in the treatment of people with
haemophilia is the development of neutralizing anti-
factor VIII (FVIII) and factor IX (FIX) antibodies
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(inhibitors) that compromise the activity of the
administered factor [1,2]. The appearance of these
inhibitors in the circulation is the outcome of a multi-
step process that involves a cascade of interactions
between different cells of the innate and adaptive
immune system in very distinct compartments. Each
step in this cascade is tightly regulated by stimulatory
and inhibitory signals that determine the activation
state of the immune cells involved and their migra-
tion into distinct lymphoid compartments [3]. Any
event that alters the balance between the signals will
have the potential to modulate these steps, and the
development of inhibitory antibodies is therefore
most likely determined by a close interaction
between different risk factors or events. The activa-
tion of CD4+ T cells that help B cells to differentiate
into antibody producing plasma cells requires an
effective interaction with antigen-presenting cells
that present FVIII or FIX peptides in the context of
MHC-class II. The effectiveness of this interaction
depends on the maturation state of the antigen-
presenting cells. This is influenced by genetic factors
determining the sensitivity of the innate immune
system to respond to certain immune stimuli and by
the local environment that provides the immune
stimuli. In recent years, stimuli of the innate immune
system have been named ‘danger signals’. Today, it is
well established that danger signals can arise from
both exogenous and endogenous sources [4]. Typical
exogenous sources are microbial agents that trigger
toll-like receptors and other microbial sensors [5,6].
Therefore, any infection and certain vaccinations
that occur at the time of treatment with the deficient
factor should be considered as potential risk factors
for the development of inhibitors. Endogenous
sources of danger signals are mostly associated with
tissue damage that involves necrotic cell death. Cells
that die by necrosis release endogenous danger
signals that stimulate the innate immune system
[4]. Severe bleeds and surgery are most likely to be
associated with such necrotic cell damage and could,
therefore, contribute to the risk for a patient to
develop inhibitors. One way to avoid necrotic cell
damage at the time of treatment would be to
administer the factor during bleeding-free intervals.
For clinical reasons this is not always possible, yet
prophylactic treatment of patients might well impose
a lower risk than on-demand treatment [7].
Several findings during the last decade clearly
indicate that genetic factors are major determinants
of the outcome. However, the influence of non-
genetic factors related to patients and treatment is
also appreciated and will likely, in many cases, be
decisive. Therefore, the better we understand the
impact of each potential risk factor and danger
signal, the better able we will be to identify the
determinants of risk for an individual patient in a
particular situation, and optimize management in the
clinical setting. To shed some light on the importance
of non-genetic candidates for inhibitor risk, the
European Haemophilia Therapy Standardisation
Board (EHTSB) – a network of haemophilia physi-
cians in Europe – reviewed the current literature on
the risk factors which have the potential to generate
danger signals for the innate immune system. The
risk factors assessed were divided into five groups:
(i) pregnancy/delivery issues and breast feeding,
(ii) age at start of treatment, reason for first infusion
and prophylactic vs. on-demand treatment, (iii)
vaccinations, infections, extravascular infusions,
blood components, concurrent immunological disor-
ders, (iv) severe bleeds, intensity of treatment,
surgery and continuous vs. bolus infusions, and (v)
type of factor concentrate.
Besides providing a comprehensive review of the
literature, the study also reports on a survey of
clinical practice among the EHTSB centres in
Europe. Consensus statements and treatment recom-
mendations are provided reflecting the European
Medicines Agency (EMEA) guidelines [8], the liter-
ature and current practice.
Methods
Literature review
The literature search was carried out in May 2008, and
updated in January 2010, using the PubMed database.
The terms used were ‘Hemophilia/haemophilia A/
immunology’[MeSH] OR ‘Hemophilia/haemophilia
B/immunology’[MeSH]) OR ‘Factor VIII/antagonists
and inhibitors’[MeSH] OR ‘Factor VIII/immunol-
ogy’[MeSH] OR ‘Factor IX/antagonists and inhibi-
tors’[MeSH] OR ‘Factor IX/immunology’[MeSH].
Further selection of appropriate studies was carried
out manually by the authors. Case–control studies,
cohort studies and case series were included, but single
case reports and abstracts were excluded.
All data were extracted from the articles by 2–4
authors and classified according to the following
definitions: a cohort study was defined as a longitu-
dinal follow-up of a group of unselected patients with
known risk factors to evaluate the outcome/inhibitor
development at the conclusion of the study. A case–
control study was defined as a cross sectional study
that included a number of patients with inhibitors
(cases) and another group of (matched) patients
without inhibitors (controls). Specified risk factors
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for inhibitor development were then analysed in both
groups. Case series were defined as a longitudinal
follow-up of a group of patients selected for certain
risk factors to evaluate the outcome/inhibitor devel-
opment at the end of the observation period.
Extracted data were used to populate a standard
form. Items included: study design; number of
patients in the study; patient characteristics (severity
of haemophilia, treatment status); inhibitor testing
(frequency, assay used and cut-off level); treatment
characteristics (type of product); analysis of the risk
factor [relative risk (RR), hazard ratio, odds ratio
(OR) or otherwise, as stated by the authors]. If no
RR or OR was given these measures were calculated
whenever possible, using the available data in the
article.
EHTSB survey
The EHTSB is an established group of internationally
recognized European experts in the field of haemo-
philia and blood clotting disorders. Founded in 2003
by Baxter, the board currently represents 24 large
European haemophilia centres in 15 countries,
taking care of >4000 patients with severe congenital
bleeding disorders from birth to adulthood. In
conjunction with the literature review, a survey was
undertaken to assess all members’ opinions of the
importance of risk factors on the development of
inhibitors and how this influenced their clinical
practice. In a subgroup of 14 EHTSB members, the
potentially most important factors involved in inhib-
itor development were discussed and listed. Based on
this risk factor selection, two questionnaires were
prepared and administered to all 24 EHTSB mem-
bers. In the first questionnaire, board members were
asked to rank each risk factor on a scale of 0–5
(0 = not important or not influential; 5 = very impor-
tant or very influential) for importance of its potential
role in inhibitor development. In the other question-
naire, the influence of the same single factors on their
clinical practice was rated on a scale of 0–100.
The consensus recommendations were formulated
following a discussion held within the subgroup of
14 members during an EHTSB meeting in Brussels on
15–16 January, 2009 and reviewed after the litera-
ture update in 2010.
Results
Pregnancy/delivery issues and breast feeding
Antenatal exposure to maternal FVIII, and breast
feeding, has been considered potentially protective
against inhibitor development [9]. Supporting this
hypothesis is the fact that human breast milk affects
normal gastrointestinal development and oral
immune tolerance [10]. Moreover, the presence of
fat globule proteins in breast milk that bear strong
homology with FVIII might facilitate immune toler-
ance in the immature neonatal system, thus decreas-
ing the likelihood of inhibitor formation [9,11].
Five studies were identified for review (Table 1)
[12–16]. Two examined breastfeeding exclusively;
two considered a variety of antenatal and perinatal
risk factors (e.g. amniocentesis, villocentesis, pre-
mature birth and caesarean section) and one recent
case–control study evaluated breast feeding as one of
the potential risk factors [16]. No association could
be found between breastfeeding and inhibitor devel-
opment in any of the studies. Furthermore, there was
no support for an association of inhibitors with other
pregnancy-related issues or premature birth. Weak-
nesses in these studies were that the duration of
follow-up was variable and not clearly defined in
each study and that confounding factors were not
taken into account.
Survey. These findings were in agreement with the
survey results from the board members, the majority
of whom rated pregnancy and delivery issues and
breast feeding of none, very low or low importance
(0–2) in clinical practice (Figs 1 and 2).
Recommendations. There are no data in the literature
indicating an association between inhibitor forma-
tion and pregnancy-related issues, mode of delivery
or breastfeeding. The board, therefore, made no
recommendations regarding these topics for the
purpose of reducing inhibitor incidence.
Age at start, reason for first infusion and
prophylactic vs. on-demand FVIII treatment
Today, children with haemophilia can look forward
to a favourable orthopaedic outcome and a good
health-related quality of life. However, the age at
which to initiate therapy and how to start treatment
is still a matter of debate. It is difficult to isolate the
age at first exposure to the deficient factor as a risk
factor for inhibitor development. Seven studies were
located that addressed these issues [13,15,17–21].
Two earlier studies [17,18] (Table 2) focused exclu-
sively on age and concluded that age at start of
treatment was inversely correlated with the risk of
developing antibodies against FVIII. Later studies,
which considered confounding factors such as the
inherited FVIII mutation and intensity of treatment,
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were unable to confirm this finding (Table 2)
[13,15,20].
Several studies have evaluated prophylactic vs. on-
demand treatment and, to a lesser extent, also
attempted to analyse the reasons for the first infusion
[13,15,19]. These studies, involving a total of 580
patients, indicate that prophylactic treatment might
play a protective role against inhibitor development.
In the recent study by Kurnik et al. [21], the dose at
the start of prophylactic treatment was also
suggested to be of importance. This study demon-
strated that minimizing immunological danger sig-
nals during the first 20 EDs may reduce the risk of
inhibitor formation.
Survey. The board members were in agreement that
these factors were found to be reasonably important
influences on the risk of inhibitor development.
However, their influence on clinical practice was
highly variable with only the use of prophylactic vs.
on-demand treatment being rated of moderate to
moderately high (3–4) significance (Figs 1and 2).
Recommendation. The EHTSB recommended that
prophylaxis should be provided for all children to
prevent bleeds. In addition, prophylaxis might exert
a favourable immunological effect to promote toler-
ance. However, to better appreciate the immunolog-
ical effect well-designed prospective studies are
needed. This is also the case for evaluating the
optimal dosing and when to start treatment. Hae-
mophilia registries and large cohort studies can
provide considerable insight. In all cases, however,
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Rating of risk factors for inhibitor developmentFig. 1. Estimation of the importance of
pregnancy and delivery issues, breast feed-
ing, age at start of treatment, reason for first
treatment and prophylactic vs. on-demand
treatment, vaccinations, infections, extra-
vascular infusions, blood components,
concurrent immunological disorders, major
bleeds, intensity of treatment, surgery,
continuous infusion, product switch and
product type on inhibitor formation.
Twenty-four members of the European
Haemophilia Therapy Standardisation
Board completed the survey and the figure
represents the percentage rating the factor













Preg Breast Age Reason Prophy Vacc Infect Exravasc Blood Imm dis Bleeds Intensity Surg CI Switch Type
Fig. 2. Results of the survey of the European Haemophilia Therapy Standardisation Board group. Participants (n = 24) were asked to rate
how each factor influenced their clinical practice on a scale of 0–100.
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Vaccinations, infections, extravascular infusions,
blood components, concurrent immunological
disorders
It has been postulated that challenges to the immune
system (such as infections or vaccinations) or genetic
factors involving immune response genes and
cytokine production might influence inhibitor
formation in patients with haemophilia [13, 22]. It
has also been suggested that extensive tissue damage
and inflammation may trigger an antibody response
against extra-vascular FVIII [22].
Our search showed that there is a paucity of studies
investigating these risk factors (Table 3) [13,16,23].
One case–control study [13] has investigated vacci-
nation or infection in 60 patients and 48 control
subjects. Infections were present, or vaccinations
performed, during active FVIII treatment in 12
patients and 11 controls. Although no apparent
association was found between vaccination or infec-
tion and the development of inhibitors, no conclu-
sions could be drawn as this was a single study in
which selection bias could not be ruled out. Similarly,
only one study that considered blood components
could be identified. This study [23] was difficult to
evaluate, as the patient group was heterogeneous
with respect to the type of blood products received.
In a recent case–control study, acute hepatitis was
frequently reported within 4 months of inhibitor
detection and did not occur at all in matched controls
[16]. HBsAg positivity was associated with inhibitor
development, suggesting a higher risk of inhibitors in
association with infection. No association with
vaccination was described.
Two studies addressed the initial exposure to
blood components and inhibitor formation [16,23].
In the case–control study, inhibitor patients had
received significantly more FVIII concentrates and
less non-concentrate products than controls. No
conclusions can, however, be drawn from these two
studies, as the study groups were small, not well-
defined and heterogenous with respect to the timing
and type of blood products received.
Survey. With the exception of infections, clinical
experience within the group would suggest that the
majority rated these factors as of moderate to low
importance (3–1) in inhibitor development (Fig. 1),
and their influence on clinical practice was also
moderate to low (Fig. 2). When rated on a scale of
0–100 there was a wide variation of opinion.
Infection was the only parameter consistently
reported to be of moderately high importance and
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Recommendation. There is insufficient evidence with
which to make recommendations about the inhibitor
risk associated with vaccinations, infections, extra-
vascular infusions, blood components and concur-
rent immunological disorders.
Theoretically, however, exposure to the deficient
factor in association with immune challenges like
vaccination and infection could increase the risk.
Therefore, while waiting for studies to be performed,
the EHTSB recommended that vaccinations should
preferentially be given subcutaneously, avoiding a
concomitant infusion of a factor concentrate. In
addition, whenever possible, replacement therapy
should be avoided in association with severe infec-
tions and the exposure to all types of blood compo-
nents minimized.
Intensity of treatment, surgery, major bleeds and
continuous vs. bolus infusion
Severe bleeds and surgery are characterized by cell
damage and the release of endogenous danger signals
that could potentially promote inhibitor develop-
ment [4]. Initially, haemostatic cover was achieved
by the use of bolus injections (BI), but more recent
studies have shown that continuous infusion (CI) is
as an attractive alternative treatment modality in
many patients [24]. The advantages of CI are that it
avoids both deep, and potentially dangerous, troughs
and unnecessarily high levels of the factor obtained
with BI, thereby improving the cost-effectiveness
[25]. However, concerns have been raised about a
potential association between the use of CI and
inhibitor development [26–29].
The literature review identified 19 full manuscripts
in this category (Table 4) [13,15,24,27,29–43]: 14
were case series, three cohort studies and one case–
control study. No studies solely evaluated severe
bleeds and the risk of inhibitor development. Inten-
sive treatment, in most instances initiated because of
a surgical procedure, was examined in 14 studies
which included a total of 412 treatments in 348
patients. Of these, 16 patients (4.6%) developed an
inhibitor. All but one of the cases was reported in
previously untreated patients (PUPs) or minimally
treated patients (MTPs), i.e. patients at high risk of
developing antibodies. Six of these patients were
treated with BI and nine with CI. Among the 229
patients defined as PTPs, only one inhibitor case was
reported. Generally speaking, evaluating CI vs. BI
was not a simple task as most of the CI patients were
subsequently treated with additional intensive BI
therapy for several days or weeks. In addition,
confounding factors were rarely considered in the
investigations and the possibility of selection bias
could not be excluded in the majority of cases.
The case–control study by Santagostino et al. [13]
did not find a higher prevalence of surgery among
inhibitor compared with non-inhibitor patients. By
contrast, two retrospective studies of PUPs demon-
strated that major surgery at any exposure day was
associated with increased inhibitor risk [15,41].The
association between inhibitor development and sur-
gical procedures and/or peak treatment moments
was even more pronounced if they occurred at the
start of exposure to FVIII. Eckhardt et al. [43]
reported an increased susceptibility of mild haemo-
philia A patients with the Arg593Cys genotype for
inhibitor development after intensity of treatment for
surgery, especially when continuous infusion was
used [43].
Survey. Within the group, severe bleeds were rated as
being of quite high importance by the majority of
physicians, but the opinion on treatment intensity,
surgery and continuous infusion were very variable
(Figs 1 and 2). All of these factors had some influence
on the clinical practice of members of the group.
Recommendation. European Haemophilia Therapy
Standardisation Board recommended that prospec-
tive studies that primarily address the potential of
intensive treatment (either with BI or CI), surgery
and severity of bleeds as risk factors for inhibitor
development are warranted. It is crucial to define a
haemostatic minimum for particular clinical situa-
tions and to use treatment regimens of comparable
intensity. Given the evidence in PUPs it is, however,
desirable to minimize intensive treatment whenever
possible to avoid treatment in association with
immune system challenges. Available data do not
support the concept that the use of CI per se in
patients with severe haemophilia is associated with a
higher risk of inhibitor development. This is further
supported by the findings in an EHTSB study of
continuous vs. bolus infusion in which only three of
659 patients (0.4%) with severe haemophilia devel-
oped inhibitors (Angelika Batorova personal com-
munication, manuscript in progress). In the case of
milder forms of haemophilia, the board recommends
further thorough study.
Factor concentrates
The ability to provide effective replacement therapy
has been a major achievement, and huge advances
have been made in the production of different types
of concentrates, ranging from cryoprecipitate to
NON-GENETIC RISK FACTORS FOR INHIBITOR FORMATION 755
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bioengineered recombinant products. Even though
direct comparisons are lacking, it has been suggested
that very high purity FVIII concentrates produced by
monoclonal or recombinant technology are more
antigenic than the older concentrates, resulting in
increased risk of inhibitor development. In reviewing
the pertinent literature, 26 relevant papers were
identified: 11 case series and 15 prospective cohort
studies. The number of participants ranged from 38
to 838 (Table 5) [1,20,23,44–66].
When comparing the immunogenicity of plasma-
derived clotting products to those obtained by
recombinant DNA technology, there was no con-
sistent agreement in the literature. In addition,
numerous concerns can be raised about the quality
of the studies. They were primarily retrospective in
design, the populations were not homogenous,
patients were treated with a large variety of
products, the methodologies were variable, and
follow-up was sometimes insufficient. In addition,
selection bias could not be ruled out in the majority
of studies, and confounding factors were not
addressed.
Apart from a few outbreaks of inhibitors caused by
a change in the manufacturing process, studies of
PTPs involving more than a thousand patients
describe an incidence of inhibitors ranging from
0.9% to 2.9%. This clearly indicates that product
immunogenicity and switching to a different product
carry with them only a small risk for inhibitor
development. In addition, PTPs are likely to be older
than untreated patients, and other confounding and
potentially contributory factors not considered will
have, in some cases, an immunological impact.
The incidence of inhibitors in PUPs and MTPs with
haemophilia A ranged from 4.4% [23] to 52% [1].
As a result of the potential influence of confounding
factors, both genetic and non-genetic, it is not
possible to fully appreciate the impact of the type
of concentrate and product immunogenicity per se. It
is also noteworthy that the incidence of inhibitors
varies between cohorts despite the use of the same
product, which underscores both the heterogeneity of
the studies and the importance of a well-character-
ized cohort for study to better appreciate the
immunogenicity of the product itself.
Survey. The issue of product switching was consid-
ered to be of moderate to low (3–2) importance and
influence on clinical practice by the majority of the
group. The type of product was considered of
moderate to low importance (no individual rated it
at 5) (Figs 1 and 2), but its influence on clinical
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Recommendations. The European Haemophilia Ther-
apy Standardisation Board concluded that in PTPs
there is no evidence to suggest that the immunoge-
nicity of various types of product will differ and that
the use of these concentrates, or a switch between
them, will be associated with a risk of inhibitor
development. Thus far, there is insufficient evidence
with regard to inhibitor risk for a treating physician
to select one product over another and recent
findings suggesting an impact of the FVIII polymor-
phism on inhibitor risk require further studies [67].
Evaluating whether the type of concentrate has the
ability to modulate the risk in PUPs in a significant
way and thereby establishing implications for the use
of different types of factor concentrates will require
well-designed, prospective clinical trials. These trials
must also consider all other aspects of product
choice. Independent of the concentrate used, EHTSB
recommended that all patients should be carefully
monitored during the high-risk period at start of
treatment.
Discussion
This review of the literature revealed a lack of data
allowing a proper appreciation of the potential
impact of a variety of non-genetic risk-factors on
inhibitor development. The most important factors
appear to be: the reason for the first infusion at
young age and the intensity of treatment. In these
situations the immune system may be exposed to
the deficient factor within the context of immune
system challenges and the occurrence of danger
signal(s). The prophylactic use of factor concen-
trates to prevent bleeds is state-of-the-art. However,
recent data also suggest that prophylaxis might
modulate the immune response to treatment when
started at young age and thereby reduce inhibitor
risk. The latter hypothesis requires more investiga-
tion, which is also the case for understanding the
optimal dosing required to allow this potential
benefit of prophylaxis to occur. For most of the
other debated non-genetic factors, the impact on the
immunological outcome is, to date, not supported
by the literature. Because the factors are often
interrelated, it is also difficult to identify the relative
contribution of each. This is also reflected by the
results of the survey carried out among the EHTSB
members, in which the impact of the majority of the
factors was extremely variable; a pattern also
recently reported in a survey by van den Berg and
Chalmers [68]. The genetic profile of the patient
will have a major impact on the immunological
outcome and must be considered. This has not been
done in the current literature. As haemophilia is a
rare disease, and inhibitors develop in a minority of
patients, the statistical power of studies addressing
these issues will, by definition, be limited. In light of
the complexity of the aetiology of inhibitor devel-
opment, future research should be directed at the
identification of early immunological markers of
high risk patients.
In 2007, the EMEA [8] produced a report that
defined many of the variables that should be consid-
ered when evaluating the literature on inhibitor
formation. Unfortunately, several of these variables
have not been included in a substantial number of
published studies, which will indeed influence the
accuracy, validity and interpretation of the data. For
example, the type of assay used to measure and to
identify the inhibitor. The Nijmegen modification of
the Bethesda assay was considered the ‘gold standard’
with a cut-off point of >0.6 BU. In addition, confir-
matory tests on a second, separately drawn sample
within a month should be performed. As seen in the
tables, however, these requirements are frequently
not adhered to by studies published in the current
literature. Moreover, the previous exposure to factor
concentrates will be of major importance. According
to the EMEA report, PUPs should be defined as those
patients who have never been exposed to clotting
factor products. Frequently, inhibitor studies involve
patients who are considered to be MTPs. This term
was considered inappropriate and these patients
should instead be defined as previously treated
patients (PTPs). This will have an impact on the
interpretation of inhibitor incidence in each cohort
described. It was also suggested that the number of
EDs should be utilized as parameters to categorize
risk rather than rely on the categories of PUP or MTP.
In the case of factor concentrate immunogenicity, it
was agreed that PTPs was the optimal group to study
to limit the impact of confounding factors. Further-
more, all studies should ideally provide patients’
characteristics, including severity of the disease, age
at first exposure, race and ethnicity, type of gene
mutation, family history of inhibitors, general health
status, reason for treatment, type of regimen and
intensity of treatment, EDs, surgery, infection and
vaccination. Most of this information is not available
in the studies performed to date.
Regarding future investigations in the area of
inhibitor development, EHTSB recommends that
the studies be carried out on well characterized,
large cohorts of severe (clotting activity <1%),
infusion-naı¨ve PUPs with consecutive enrolment.
The only exception to this recommendation is the
evaluation of immunogenicity of new factor concen-
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trates which, according to the EMEA guidelines,
should first be carried out in PTPs. Potentially
confounding factors should be addressed and genetic
factors taken into account. Validated assays (e.g.
Nijmegen) for inhibitor analysis should preferably be
performed in a central laboratory with a pre-defined
cut-off value and, in a case where an inhibitor is
detected, confirmed with another test within the
shortest possible interval. Patients who develop an
inhibitor should be classified by clear criteria as high
responders (‡5 BU), low responders (<5 BU) and
whether the inhibitor is transient (disappearing
within 3 months without a change in treatment
regimen, or disappearing) or not. Enzyme linked
immune sorbent assay (ELISA) should also be per-
formed to detect all antibodies produced against the
deficient factor.
Well-conducted studies will contribute to our
understanding of the pathophysiology of inhibitor
development, thereby enabling the use of treatment
approaches with the potential to minimize inhibitor
development in patients with haemophilia.
Acknowledgements
The EHTSB is a collaborative independent network
of European haemophilia centres sponsored by an
unrestricted grant from Baxter.
Members of the EHTSB
C. Altisent, Barcelona, Spain; J. Astermark, Malmo¨,
Sweden; A. Batorova, Bratislava, Slovakia; P. de
Moerloose, Geneva, Switzerland; G. Dolan, Not-
tingham, UK; K. Fijnvandraat, Amsterdam, The
Netherlands; K. Fischer, Utrecht, The Netherlands;
A. Gringeri, Milan, Italy; C. Hermans, Brussels,
Belgium; P. A. Holme, Oslo, Norway; K. Holstein,
Hamburg, Germany; M. Joa˜o Diniz, Lisbon, Portu-
gal; A. Karafoulidou, Athens, Greece; R. Klamroth,
Berlin, Germany; T. Lambert, Paris, France;
R. Lassila, Helsinki, Finland; G. Lavigne-Lissalde,
Nıˆmes, France; F. Lope´z, La Corunˇa, Spain; R. Pe´rez,
Seville, Spain; M. Richards, Leeds, UK; A. Rocino,
Naples, Italy; M. Schiavoni, Bari, Italy; M. von
Depka, Hannover, Germany; J. Windyga, Warsaw,
Poland.
Disclosures
Dr Astermark has received research funds from
Baxter, Bayer, Wyeth, Octapharma, CSL Behring
and Grifols. He has also received honoraria for
organising education sessions, for speaking at scien-
tific meetings or for consultancy services from
Baxter, Bayer, Wyeth, Octapharma, CSL Behring,
Novo Nordisk, and Biovitrum. Dr Batorova has
received honoraria for organizing educational session
and speaking at scientific meetings from Bayer,
Octapharma, Novo Nordisk, and consultancy fees
from Baxter. Dr Holme has received honoraria for
speaking and research funds from Baxter and Novo
Nordisk. Dr Rocino has received honoraria for
speaking, organising educational sessions or consul-
tancy services from Baxter, Bayer, CSL Behring,
Novo Nordisk and Wyeth Lederle. Dr Fijnvandraat
has received consultancy fees from Baxter. Dr Reipert
is an employee of Baxter Bioscience. Dr Windyga has
received research funds from Baxter, Bayer, Novo
Nordisk, Wyeth, Octapharma and honoraria for
speaking at scientific meetings or for consultancy
services from Baxter, Bayer, Octapharma, CSL
Behring, Novo Nordisk, and Biovitrum. All other
authors have no disclosures to make.
References
1 Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development
of factor VIII and factor IX inhibitors in haemophiliacs. Lancet
1992; 339: 594–8.
2 Hoyer LW, Aledort LM, Lusher JM, Reisner HM, White GC. The
incidence of factor VIII inhibitors in patients with severe haemo-
philia A. In: Aledort LM, Hoyer LW, Lusher JM, Reisner HM,
White GC eds. Inhibitors to Coagulation Factors. New York,
USA: Plenum, 1995: 35–45.
3 Reipert BM, den Helden PMW, Schwartz H-P, Hausl C. Mecha-
nism of action of immune tolerance induction against factor VII in
patients with congenital haemophilia A and factor VIII inhibitors.
Br J Haematol 2006; 136: 12–25.
4 Kono H, Rock KL. How dying cells alert the immune system to
danger. Nat Rev Immunol 2008; 8: 279–89.
5 Takeda K, Akira S. Toll-like receptors in innate immunity. Int
Immun 2005; 17: 1–14.
6 Meylan E, Tschopp J, Karin M. Intracellular pattern recognition
receptors in the host response. Nature 2006; 442: 39–44.
7 Mancuso ME, Graca L, Auerswald G, Santagostino E. Haemo-
philia care in children – benefits of early prophylaxis for inhibitor
prevention. Haemophilia 2009; 15(Suppl. 1): 8–14.
8 EMEA Report of Expert Meeting on Factor VIII Products and
Inhibitor Development. London: EMEA, 22 February 2007 (Doc
Ref EMEA/CHMP/BPWP/123835/2006).
9 Yee TT, Lee CA. Oral immune tolerance induction to factor VIII
via breast milk, a possibility? Haemophilia 2000; 6: 591.
10 Hanson LA. Breast feeding provides passive and likely long-lasting
active immunity. Ann Allergy Asthma Immunol 1998; 81: 523–37.
11 Larocca D, Peterson JA, Urrea R, Kuniyoshi J, Bistrain AM,
Ceriani RL. A Mr 46,000 human milk fat globule protein that is
highly expressed in human breast tumors contains factor VIII-like
domains. Cancer Res 1991; 51: 4994–8.
12 Knobe KE, Tengborn LI, Petrini P, Ljung RCR. Breastfeeding does
not influence the development of inhibitors in haemophilia.
Haemophilia 2002; 8: 657–9.
13 Santagostino E, Mancuso ME, Rocino A et al. Environmental risk
factors for inhibitor development in children with haemophilia A:
case–control study. Br J Haematol 2005; 130: 422–7.
764 J. ASTERMARK et al.
Haemophilia (2010), 16, 747–766  2010 Blackwell Publishing Ltd
14 Jansen IMJ, Fischer K, van der Bom JG, van den Berg HM. No
protective effect of breastfeeding on inhibitor formation in severe
haemophilia. Ped Hematol Oncol 2005; 22: 575–80.
15 Gouw SC, van der Bom JG, van den Berg HM, for the CANAL
Study Group. Treatment-related risk factors of inhibitor devel-
opment in previously untreated patients with haemophilia A: The
CANAL cohort study. Blood 2007; 109: 4648–54.
16 Ragni MV, Ojeifo O, Feng J et al. Risk factors for inhibitor for-
mation in haemophilia: a prevalent case–control study. Haemo-
philia 2009; 15: 1074–82.
17 Lorenzo JI, Lo´pez A, Altisent C, Aznar JA. Incidence of factor VIII
inhibitors in severe haemophilia: the importance of patient age. Br
J Haematol 2001; 113: 600–3.
18 van der Bom JG, Mauser-Bunschoten P, Fischer K. Age at first
treatment and immune tolerance to factor VIII in severe hemo-
philia. Thromb Haemost 2003; 89: 475–9.
19 Morado M, Villar A, Jime´nez-Yuste V, Quintana M, Hernandez
Navarro F. Prophylactic treatment effects on inhibitor risk:
experience in one centre. Haemophilia 2005; 11: 79–83.
20 Chalmers EA, Brown SA, Keeling D et al. Early factor VIII
exposure and subsequent inhibitor development in children with
severe haemophilia A. Haemophilia 2007; 13: 149–55.
21 Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B,
Auerswald G. New early prophylaxis regimen that avoids
immunological danger signals can reduce FVIII inhibitor devel-
opment. Haemophilia 2009; Oct 29 [Epub ahead of print]. DOI:
10.1111/j.1365-2516.2009.02122.x.
22 Oldenburg J, Schro¨der J, Brackmann H-H, Mu¨ller-Reible C,
Schwaab R, Tuddenham E. Environmental and genetic factors
influencing inhibitor development. Semin Hematol 2004;
41(Suppl. 1): 82–8.
23 Yee TT, Pasi KJ, Lilley PA, Lee CA. Factor VIII inhibitors in
haemophiliacs: a single-centre experience over 34 years, 1964-97.
Br J Haematol 1999; 104: 909–14.
24 Batorova A, Martinowitz U. Intermittent injections vs. continuous
infusion of factor VIII in haemophilia patients undergoing major
surgery. Br J Haematol 2000; 110: 715–20.
25 Hathaway WE, Christian MJ, Clarke SL, Hasiba U. Comparison
of continuous and intermittent factor VIII concentrate therapy in
haemophilia A. Am J Hematol 1984; 17: 85–8.
26 White B, Cotter M, Byrne M, O’Shea E, Smith OP. High
responding factor VIII inhibitors in mild haemophilia – is there a
link with recent changes in clinical practice? Haemophilia 2000;
6: 113–5.
27 Sharathkumar A, Lillicrap D, Blanchette S et al. Intensive expo-
sure to factor VIII is a risk factor for inhibitor development in mild
haemophilia A. J Thromb Haemost 2003; 1: 1228–36.
28 Koestenberger M, Leschnik B, Muntean W. More on: mild hae-
mophilia A and inhibitor development. J Thromb Haemost 2004;
2: 676.
29 von Auer CH, Oldenburg J, von Depka M et al. Inhibitor
development in patients with haemophilia A after continuous
infusion of FVIII concentrates. Ann N Y Acad Sci 2005; 1051:
498–505.
30 White GC II, Courter S, Bray GL, Lee M, Gomperts ED. A mul-
ticenter study of recombinant factor VIII (Recombinate) in
previously treated patients with hemophilia A. Thromb Haemost
1997; 77: 660–7.
31 Berntorp E. Second generation, B-domain deleted recombinant
factor VIII. Thromb Haemost 1997; 78: 256–60.
32 Campbell PJ, Rickard KA. Continuous and intermittent infusion
of coagulation factor concentrates in patients undergoing surgery:
a single centre Australian experience. Aust N Z J Med 1998; 28:
440–5.
33 Rochat C, McFadyen ML, Schwyzer R, Gilham A, Cruickshank
A-L. Continuous infusion of intermediate-purity factor VIII in
haemophilia A patients undergoing elective surgery. Haemophilia
1999; 5: 181–6.
34 Tagariello G, Davoli PG, Gajo GB et al. Safety and efficacy
of high-purity concentrates in haemophiliac patients undergo-
ing surgery by continuous infusion. Haemophilia 1999; 5: 426–
30.
35 Scharrer I, Brackmann H-H, Sultan Y et al. Efficacy of a sucrose-
formulated recombinant factor VIII used for 22 surgical proce-
dures in patients with severe haemophilia A. Haemophilia 2000;
6: 614–8.
36 Dingli D, Gastineau DA, Gilchrist GS, Nichols WL, Wilke JL.
Continuous factor VII infusion therapy in patients with haemo-
philia A undergoing surgical procedures with plasma-derived or
recombinant factor VIII concentrates. Haemophilia 2002; 8: 629–
34.
37 Ghosh K, Jijina F, Shetty S, Madkaikar M, Mohanty D. First-time
development of FVIII inhibitor in haemophilia patients during the
postoperative period. Haemophilia 2002; 8: 776–80.
38 Scharrer I, and the Kogenate Bayer Study Group. Experience
with KOGENATE Bayer in surgical procedures. Haemophilia
2002; 8: 15–8.
39 Mulcahy R, Walsh M, Scully M-F. Retrospective audit of a con-
tinuous infusion protocol for haemophilia A at a single haemo-
philia treatment centre. Haemophilia 2005; 11: 208–15.
40 Bidlingmaier C, Deml M-M, Kurnik K. Continuous infusion of
factor concentrates in children with haemophilia A in comparison
with bolus injections. Haemophilia 2006; 12: 212–7.
41 Gouw SC, van den Berg HM, Le Cessie S, van der Bom JG.
Treatment characteristics and the risk of inhibitor development: a
multicentre cohort study among previously untreated patients
with severe hemophilia A. J Thromb Haemost 2007; 5: 1383–90.
42 Negrier C, Shapiro A, Berntorp E et al. Surgical evaluation of
recombinant factor VII prepared using a plasma/albumin-free
method: efficacy and safety of Advate in previously treated
patients. Thromb Haemost 2008; 100: 217–23.
43 Eckhardt CL, Menke LA, van Ommen CH et al. Intensive peri-
operative use of factor VIII and the Arg593 ﬁ Cys mutation are
risk factors for inhibitor development in mild/moderate haemo-
philia A. J Thromb Haemost 2009; 7: 930–7.
44 Lusher JM, Salzman PM, and the Monoclate Study Group. Viral
safety and inhibitor development associated with factor VIIIC
ultra-purified from plasma in hemophiliacs previously unexposed
to factor VIIIC concentrates. Semin Hamatol 1990; 27(Suppl. 2):
1–7.
45 Addiego JE, Gomperts E, Liu S-L et al. Treatment of hemophilia A
with a highly purified factor VII concentrate prepared by anti-
FVIIIc immunoaffinity chromatography. Thromb Haemost 1992;
67: 19–27.
46 Addiego J, Kasper C, Ablidgaard C et al. Frequency of inhibitor
development in haemophiliacs treated with low-purity factor VIII.
Lancet 1993; 342: 462–4.
47 Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant
factor VIII for the treatment of previously untreated patients with
haemophilia A. Safety, efficacy, and development of inhibitors.
Kogenate Previously Untreated Patient Study Group. N Eng J Med
1993; 328: 453–9.
48 Rosendaal FR, Nieuwenhuis HK, van den Berg HM et al.
A sudden increase in factor VIII inhibitor development in multi-
transfused hemophilia A patients in The Netherlands. Blood 1993;
81: 2180–6.
49 De Biasi R, Pocino A, Papa ML, Salerno E, Mastrullo L, De Biasi
D. Incidence of factor VII inhibitor development in hemophilia A
patients treated with less pure plasma derived concentrates.
Thromb Haemost 1994; 71: 544–7.
50 Bray GL, Gomperts ED, Courter S et al. A multicenter study of
recombinant factor VIII (Recombinate): safety, efficacy, and
inhibitor risk in previously treated patients with hemophilia A.
Blood 1994; 83: 2428–35.
51 Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor
VIII inhibitor development in the Canadian hemophilia A popu-
NON-GENETIC RISK FACTORS FOR INHIBITOR FORMATION 765
 2010 Blackwell Publishing Ltd Haemophilia (2010), 16, 747–766
lation following the widespread introduction of recombinant
factor VIII replacement therapy. Transfus Sci 1998; 19: 139–48.
52 Courter SG, Bedrosian CL. Clinical evaluation of B-domain
deleted recombinant factor VIII in previously untreated patients.
Semin Hematol 2001; 38(Suppl. 4): 52–9.
53 Courter SC, Bedrosian CL. Clinical evaluation of B-domain
deleted recombinant factor VII in previously treated patients.
Semin Hematol 2001; 38(Suppl. 4): 44–51.
54 Knobe KE, Sjo¨rin E, Tengborn LI, Petrini P, Ljung RCR. Inhibi-
tors in the Swedish population with severe haemophilia A and B: a
20-year survey. Acta Paediatr 2002; 91: 910–4.
55 Kreuz W, Ettingshausen CE, Zyschka A, Oldenburg J, Martinez
Saguer I et al. Inhibitor development in previously untreated
patients with haemophilia A: a prospective long-term follow-up
comparing plasma-derived and recombinant products. Semin
Thromb Hemost 2002; 28: 285–90.
56 Kreuz W, Ettinghousen CE, Auerswald G et al. Epidemiology of
inhibitors and current treatment strategies. Haematologica 2003;
88(Suppl. 9): 17–20.
57 Lusher JM, Lee CA, Kessler CM, Bedrosian CL, for the Refacto
Phase 3 Study Group. The safety and efficacy of B-domain deleted
recombinant factor VIII concentrate in patients with severe hae-
mophilia A. Haemophilia 2003; 9: 38–49.
58 Yoshioka A, Fukutake K, Takamatsu J, Shirahata A, and the
Kogenate Post-Marketing Surveillance Study Group. Clinical
evaluation of a recombinant factor VIII preparation (Kogenate) in
previously untreated patients with hemophilia A. Int J Hematol
2003; 78: 467–74.
59 Kreuz W, Gill JC, Rothschild C et al. Full-length sucrose-formu-
lated recombinant factor VIII for treatment of previously
untreated or minimally treated young children with severe
haemophilia A. Thromb Haemost 2005; 93: 457–67.
60 Kreuz W, Auerswald G, Budde U, Klose HJ, Lenk H, and the
GTH-PUP-Study Group. Inhibitor incidence in previously
untreated patients (PUPs) with haemophilia A and B. A prospective
multi-center study of the pediatric committee of the German, Swiss
and Austrian Society for Thrombosis and Hemostasis Research
(GTH). In: Scharrer I, Scharrer W eds. 35th Hemophilia Sympo-
sium Hamburg 2004. Heidelberg: Springer Verlag, 2006: 34–7.
61 Goudemand J, Rothschild C, Demiguel V et al. Influence of the
type of factor VIII inhibitors in previously untreated patients with
severe hemophilia A. Blood 2006; 107: 46–51.
62 Gringeri A, Monzini M, Tagliarello G, Scaraggi FA, Mannucci
PM, and the Emoclot 15 Study Members. Occurrence of inhibitors
in previously untreated or minimally treated patients with hae-
mophilia A after exposure to a plasma-derived solvent-detergent
factor VIII concentrate. Haemophilia 2006; 12: 126–31.
63 Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in
a cohort of 838 males with hemophilia A previously treated
with factor VIII concentrates. J Thromb Haemost 2006; 4:
2576–81.
64 Gouw SC, van der Bom JG, Auerswald G et al. Recombinant
versus plasma-derived factor VIII products and the development
of inhibitors in previously untreated patients with severe
hemophilia A: the CANAL cohort study. Blood 2007; 109:
4693–7.
65 Delumeau J-C, Ikegawa C, Yokoyama C, Haupt V. An observa-
tional study of sucrose-formulated recombinant factor VIII for
Japanese patients with haemophilia A. Thromb Haemost 2008;
100: 32–7.
66 Musso R, Santagostino E, Faradji A, Iorio A, van der Meer J et al.
Safety and efficacy of sucrose-formulated full-length recombinant
factor VIII: experience in the standard clinical setting. Thromb
Haemost 2008; 99: 52–8.
67 Viel KR, Ameri A, Abshire TC et al. Inhibitors of factor VIII in
black patients with hemophilia. N Engl J Med 2009; 360:
1618–27.
68 van den Berg HM, Chalmers EA. Clinical prediction models for
inhibitor development in severe haemophilia A. J Thromb Hae-
most 2009; 7(Suppl.1): 98–102.
766 J. ASTERMARK et al.
Haemophilia (2010), 16, 747–766  2010 Blackwell Publishing Ltd
